Refine
Has Fulltext
- yes (208)
Is part of the Bibliography
- yes (208)
Year of publication
Document Type
- Journal article (106)
- Doctoral Thesis (100)
- Conference Proceeding (1)
- Review (1)
Language
- English (208) (remove)
Keywords
- HPLC (9)
- Bioverfügbarkeit (7)
- Instrumentelle Analytik (6)
- Löslichkeit (6)
- Muscarinrezeptor (6)
- NMR-Spektroskopie (6)
- Aminosäuren (5)
- Arzneimittel (5)
- Impurity Profiling (5)
- Ligand <Biochemie> (5)
- population pharmacokinetics (5)
- synthesis (5)
- Chemische Reinheit (4)
- Extrazelluläre Matrix (4)
- LC-MS/MS (4)
- Organische Synthese (4)
- Pharmakodynamik (4)
- Pharmakokinetik (4)
- Synthese (4)
- Synthesis (4)
- Targeted drug delivery (4)
- pharmacokinetics (4)
- therapeutic drug monitoring (4)
- Amino acids (3)
- Antibiotikum (3)
- Arzneimitteldesign (3)
- Biomarker (3)
- Charged Aerosol Detection (3)
- Formulierungsentwicklung (3)
- Interleukin 4 (3)
- Ionic Liquids (3)
- Kontrollierte Wirkstofffreisetzung (3)
- LC-MS (3)
- Metabolismus (3)
- Naturstoff (3)
- Pharmaceutical Analysis (3)
- Solubilisation (3)
- Tuberkelbakterium (3)
- Verunreinigung (3)
- Wirkstofffreisetzung (3)
- antibiotics (3)
- capillary electrophoresis (3)
- charged aerosol detector (3)
- chemistry (3)
- click chemistry (3)
- drug delivery (3)
- drug design (3)
- human (3)
- medicine (3)
- metabolism (3)
- muscarinic receptors (3)
- natural products (3)
- nutrition (3)
- polyphenols (3)
- positron emission tomography (3)
- protein binding (3)
- solubility (3)
- ARONJ (2)
- Agonist (2)
- Alzheimerkrankheit (2)
- Alzheimer’s disease (2)
- Analoga (2)
- Antimikrobieller Wirkstoff (2)
- Arzneimittelforschung (2)
- Arzneimittelüberwachung (2)
- Bitopische Liganden (2)
- Butyrylcholinesterase (2)
- Candida albicans (2)
- Chemie (2)
- Chemische Synthese (2)
- Cholinesterase (2)
- Chromatographie (2)
- Cytokine (2)
- Enterobacteriaceae (2)
- Ernährung (2)
- Fettsäurebiosynthese (2)
- Fibroblastenwachstumsfaktor (2)
- Flavonoids (2)
- Formulation development (2)
- Formulierung (2)
- GTP-bindende Proteine (2)
- Imatinib (2)
- Inhibitor (2)
- Insulin-like Growth Factor I (2)
- Kapillarelektrophorese (2)
- Lebensmittelchemie (2)
- Lipide (2)
- Massenspektrometrie (2)
- Medizin (2)
- NMR spectroscopy (2)
- Permeabilität (2)
- Pharmacokinetic (2)
- Pharmazeutischer Hilfsstoff (2)
- Polyethylenglykole (2)
- Polymere (2)
- Poorly water soluble drugs (2)
- Populationskinetik (2)
- Populationspharmakokinetik (2)
- Positronen-Emissions-Tomografie (2)
- Protease-sensitive release (2)
- Pycnogenol (2)
- Qualitätskontrolle (2)
- Reinheitsanalytik (2)
- S-ADAPT (2)
- Stabilität (2)
- Staphylococcus aureus (2)
- Struktur-Aktivitäts-Beziehung (2)
- Supersaturation (2)
- Tandem-Massenspektrometrie (2)
- Tissue Engineering (2)
- Trypanosomiase (2)
- Tryptophan (2)
- Valeriana wallichii (2)
- Wirkstoff (2)
- allometric scaling (2)
- antileishmanial (2)
- azobenzenes (2)
- baclofen (2)
- biomarker (2)
- body composition (2)
- body size (2)
- butyrylcholinesterase (2)
- chiral separation (2)
- clinical study (2)
- crystal structure (2)
- cystic fibrosis patients (2)
- cytochrome P450 3A4 (CYP3A4) (2)
- dendritic cells (2)
- drugs (2)
- drug–drug interactions (DDIs) (2)
- dualsteric ligands (2)
- endothelium (2)
- estrogens (2)
- extracellular matrix (2)
- fatty acid biosynthesis (2)
- gene expression (2)
- graft versus host disease (2)
- healthy volunteers (2)
- human breast (2)
- impurity profiling (2)
- in vitro (2)
- kinetics (2)
- leishmaniasis (2)
- liquid chromatography (2)
- marine sponge (2)
- mass spectrometry (2)
- molecular modeling (2)
- multiple linear regression (2)
- neuroprotection (2)
- norepinephrine transporter (2)
- octopamine (2)
- oral bioavailability (2)
- osteoarthritis (2)
- osteonecrosis of the jaw (2)
- osteoradionecrosis (2)
- permeability (2)
- pharmaceutical analysis (2)
- pharmacodynamics (2)
- physiologically based pharmacokinetic (PBPK) modeling (2)
- screening (2)
- staphylococcus aureus (2)
- strategy (2)
- structure-activity relationship (2)
- structure-activity relationships (2)
- sympathetic nervous system (2)
- therapy (2)
- thermogenesis (2)
- ultrafiltration (2)
- 1 (1)
- 17beta-Estradiol (1)
- 17beta-estradiol (1)
- 2,5-diketopiperazines (1)
- 2-Thiazaphospholidines (1)
- 2-a:6 (1)
- 2-chloro (1)
- 2-halo (1)
- 2-imino- (1)
- 3 (1)
- 5-a']diindol (1)
- 5-a']diindole (1)
- 5-b']diindol (1)
- 5-b']diindole (1)
- 5]diazocino[1 (1)
- 77-LH-28-1 (1)
- AAA+ ATPase p97 (1)
- AChE inhibitor (1)
- AD mouse modele (1)
- ADAMTS (1)
- AGP (1)
- AOM/DSS (1)
- Acetaminophen (1)
- Acetylcysteinderivate (1)
- Achillea Fragrantissima (1)
- Acrylamid (1)
- Acrylamide (1)
- Actinomycetes (1)
- Active pharmaceutical ingredients (1)
- Adhäsion (1)
- Aescin (1)
- African Trypanosomiasis (1)
- Akt (1)
- Akt/PKB (1)
- Albendazol (1)
- Aldehyde (1)
- Alkamiden (1)
- Alkamides (1)
- Alkylpyrazine (1)
- Allosteric Modulator (1)
- Allosterisch Modurator (1)
- Allosterischer Effektor (1)
- Alzheimer (1)
- Alzheimer's diseas (1)
- Alzheimer's disease (1)
- Alzheimer′s disease (1)
- Amino Acids (1)
- Aminosäure (1)
- Anacardic acid derivatives (1)
- Anacardsäurederivate (1)
- Analyse (1)
- Analytical Quality by Design (1)
- Analytik (1)
- Anthocyane (1)
- Antibiotic (1)
- Antibiotika (1)
- Antiinfektiva (1)
- Antikörper (1)
- Antitrypanosomal (1)
- Antitrypanosomen (1)
- Antitumor (1)
- Arthrose (1)
- Arzneimittelwechselwirkung (1)
- Arzneistoffanalytik (1)
- Asymmetrie (1)
- Autoradiographie (1)
- Aziridines (1)
- BRAF mutation (1)
- Baclofen (1)
- Bakterien (1)
- Benzimidazole (1)
- Beta-2-Rezeptor (1)
- Bile (1)
- Bioaccessibility (1)
- Bioanalytik (1)
- Bioavailability (1)
- Bioconjugate (1)
- Biodistribution (1)
- Biologische Aktivität (1)
- Biologischer Abbau (1)
- Bioreactor System (1)
- Biosensor (1)
- Biotransformation (1)
- Bisoprolol (1)
- Bitopic Ligands (1)
- Blockcopolymere (1)
- Blut-Hirn-Schranke (1)
- Brustdrüse (1)
- Burkholderia pseudomallei Mip (1)
- C-3-substituiert (1)
- C-3-substituted (1)
- CAD detection (1)
- CAR T cells (1)
- CAR T-Zellen (1)
- CFC replacements (1)
- CO‐releasing molecules (CORMs) (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cabozantinib (1)
- Candida auris (1)
- Cannabinoid Receptor (1)
- Capillary Electrophoresis (1)
- Carbamate (1)
- Carbocistein (1)
- Carboxylates (1)
- Cecropia telenitida (1)
- Cerulenin (1)
- Characterization (1)
- Charged Aerosol Detektion (1)
- Charged aerosol detection (1)
- Charged aerosol detector (CAD) (1)
- Chemical stability (1)
- Chemometric (1)
- Chemometrie (1)
- Chewing Gum (1)
- Chinolon <2-> (1)
- Chinolonamide (1)
- Chinolonderivate (1)
- Chiralität (1)
- Chlorfluorkohlenstoffe (1)
- Cholinesteraseinhibitor (1)
- Chondrogenesis (1)
- Chromatographischer Detektor (1)
- Chromone (1)
- Citrus (1)
- Click-Chemie (1)
- Codon (1)
- Commercial preparations (1)
- Computational chemistry (1)
- Computational drug-design (1)
- Contaminants (1)
- Controlled release (1)
- Corona charged aerosol detector (1)
- Counterfeit Medicines (1)
- Cutaneous leishmaniasis (1)
- Cyclo-AMP (1)
- Cyclo-GMP (1)
- Cytochrom P-450 (1)
- Cytotoxicity (1)
- Cytotoxizität (1)
- DNA-encoded library synthesis (1)
- DNA-tagged amines (1)
- DPP IV (1)
- Deep Eutectics (1)
- Derivsatisierung (1)
- Detektor (1)
- Diabetes mellitus (1)
- Diagnostik (1)
- Dickdarmkrebs (1)
- Dimere (1)
- Dimerisierung (1)
- Dosis (1)
- Dosislinearität (1)
- Drug delivery platform (1)
- Drug delivery platforms (1)
- Drug design (1)
- Drug form selection (1)
- EDC-NHS chemistry (1)
- EDTA (1)
- East Africa (1)
- Effluxpumpen (1)
- Electrospinning (1)
- Elektronensprayionisations-Massenspektrometrie (1)
- Enantiomere (1)
- Enantiomerentrennung (1)
- Enantiomerüberschuss (1)
- Enantioselektivität (1)
- Encapsulation (1)
- Endothel (1)
- Enoyl-Reduktase (1)
- Enoyl-acyl-carrier-protein-Reductase (1)
- Enoyl-acyl-carrier-protein-Reductase <Enoyl-[acyl-carrier-protein]-Reductase> (1)
- Enzym (1)
- Enzyme inhibitor (1)
- Enzyminhibitor (1)
- Ephedrin (1)
- Eriodictyon californicum (1)
- Ersatzstoff (1)
- Escherichia coli (1)
- Estradiol (1)
- Estrogens (1)
- Europäsches Arzneibuch (1)
- Excipient selection (1)
- Expiry date (1)
- Extrakt (1)
- FCKW-Ersatzstoffe (1)
- FGF (1)
- FGF-2 (1)
- FRET (1)
- FV45 (1)
- FabI (1)
- Fatty acids (1)
- Fertigarzneimittel (1)
- Fett (1)
- Fettgewebe (1)
- Fettkennzahlen (1)
- Fettsäurestoffwechsel (1)
- Flavoniden (1)
- Flavonoide (1)
- Flavonoinds (1)
- Fluoreszenz (1)
- Fluoreszenz-Resonanz-Energie-Transfer (1)
- Fluoreszenzliganden (1)
- Fluoreszenzmikroskopie (1)
- Fluoreszenzpolarisation (1)
- Fluorine (1)
- Fluorverbindungen (1)
- Flux (1)
- Flüssigkeitschromatographie (1)
- Formulation (1)
- Functional properties (1)
- Funktionalisierung <Chemie> (1)
- Funktionalisierung von elektrogesponnenen Fasern (1)
- Fälschung (1)
- G-Protein gekoppelte Rezeptor (1)
- G-protein coupled receptor (1)
- GABA (1)
- GABA-Rezeptor-Agonist (1)
- GABAB (1)
- GABAB receptor agonists (1)
- GABA\(_{A}\) receptor (1)
- GABA\(_{B}\) (1)
- GPCR (1)
- Galle (1)
- Galle <Sekret> (1)
- Gallensalze (1)
- Gas chromatography (1)
- Gaschromatographie (1)
- Gentamicin (1)
- Geschichte (1)
- Glutamate (1)
- Glycinrezeptor (1)
- Glycoengineering (1)
- Glykosylierung (1)
- Gradient boosted trees (GBT) (1)
- Gyrasehemmer (1)
- HIV (1)
- HNSCC (1)
- HPLC-MS (1)
- HPLC–MS (1)
- Hepatotoxizität (1)
- High-performance liquid chromatography (1)
- High-performance liquid chromatography (HPLC) (1)
- Humane Afrikanische Trypanosomiasis (1)
- Hybrid (1)
- Hybrid GPCR Ligands (1)
- Hybrid-Molecules (1)
- Hybridliganden (1)
- Hydrogen-deuterium (1)
- Hydroperoxide (1)
- Hypoxia (1)
- Hypoxie (1)
- Hülsenfrüchte (1)
- IGF-I (1)
- IR (1)
- ISPMF (1)
- Ibuprofen (1)
- Imidates (1)
- Imidoyl halides (1)
- Impact-Faktor (1)
- In vitro (1)
- In vivo (1)
- In vivo studies (1)
- InhA (1)
- Inhalation (1)
- Inhibition (1)
- Insulin-like Growth Factor (1)
- Insulin-like growth factor-I (1)
- Integrasen (1)
- Interferon <alpha-2a-> (1)
- Ion Pairs (1)
- Ionic Liquid (1)
- Ionische Flüssigkeit (1)
- Isocyanate (1)
- Isolation and Characterization (1)
- Isotopenverhältnis-Massenspektrometrie (1)
- JAK inhibitor (1)
- Karibisches Meer (1)
- KasA (1)
- Kaugummi (1)
- Ketamin (1)
- Ketoacyl-ACP-Synthase <beta-> (1)
- Ketoacyl-ACP-synthase (1)
- Kiefernrindenextrakt (1)
- Kinaseinhibitor (1)
- Klebsiella pneumoniae (1)
- Klinische Studie (1)
- Knochenpenetration (1)
- Knorpelbildung (1)
- Kohlenhydrate (1)
- Kohlenmonoxid (1)
- Kokristallisation (1)
- Konjugation (1)
- Kristall (1)
- Kristallstruktur (1)
- LC-ESI/MS/MS (1)
- LMICS (1)
- Lactamantibiotikum <beta-> (1)
- Lebensmittelprodukte (1)
- Leber (1)
- Lebertoxizität (1)
- Legionella pneumophila (1)
- Legionnaires' Disease (1)
- Legionärskrankheit (1)
- Leishmania (1)
- Leishmaniose (1)
- Library of Phytochemicals (1)
- Library of plant species (1)
- Lipid-Peroxide (1)
- Liposomen (1)
- Low-income Countries (1)
- LpxC inhibitors (1)
- Lungenentzündung (1)
- Lungenkrebs (1)
- Lungenperfusionsmodell (1)
- M1 Muscarinic Receptor (1)
- M2 (1)
- M4 (1)
- MDR (1)
- MIR-Spektroskopie (1)
- MRONJ (1)
- MRSA (1)
- MYCNv (1)
- Makrophage (1)
- Malaria (1)
- Manganese Carbonyl ligands (1)
- Markierte Verbindungen (1)
- Masspectrometry (1)
- Matrix Effekte (1)
- Maus (1)
- Mebendazol (1)
- Melatonin (1)
- Merkaptursäuren (1)
- Metabolism (1)
- Method Validation (1)
- Microglia (1)
- Microwave Assisted Extraction (1)
- Mikrosphären (1)
- Milchdrüse (1)
- Mip (1)
- Mip Inhibitoren (1)
- Mip inhibitor (1)
- Mitsunobu (1)
- Modellierung (1)
- Modifikation von Biokeramiken (1)
- Molecular modelling (1)
- Molekular Modeling (1)
- Molekulardesign (1)
- Molekulardynamik (1)
- Monoklonaler Antikörper (1)
- Monomere (1)
- Monte Carlo Simulation (1)
- Monte Carlo simulation (1)
- Mucus (1)
- Mukovisdizose (1)
- Mukoviszidose (1)
- Multidrugresistant (1)
- Muscarinic receptor (1)
- Muskarinrezeptor (1)
- Muskelatrophie (1)
- Myositis (1)
- NIR-Spektroskopie (1)
- NMR Spektroskopie (1)
- NOX-Inhibitoren (1)
- Naproxen (1)
- Natural product hybrids (1)
- Nature-Insipired Synthesis (1)
- Neuroprotection (1)
- Neuroprotektion (1)
- ONJ (1)
- Oberflächenfunktionalisierung (1)
- Opiatrezeptor (1)
- Osmunda regalis (1)
- Osteoarthritis (1)
- PDGF (1)
- PDGFR (1)
- PET (1)
- PI3K/Akt/mTor pathway (1)
- PPIase (1)
- Paeonia (1)
- Paracetamol (1)
- Paraffin (1)
- Parameter Quality Oil (1)
- Parenteral (1)
- Peptidsynthese (1)
- Peroxidzahl (1)
- Pflanzen (1)
- Pharmacokinetics (1)
- Pharmakologie (1)
- Pharmakometrie (1)
- Pharmakotherapie (1)
- Pharmazie (1)
- Phase separation (1)
- Phenolic acids (1)
- Pilocarpin (1)
- Pilokarpin (1)
- Plant extracts (1)
- Plants (1)
- Platelet-derived Growth Factor (1)
- Point-of-Care-testing (1)
- Polyglycerol (1)
- Polymilchsäure (1)
- Polyphenole (1)
- Poorly water-soluble drug (1)
- Praziquantel (1)
- Probenaufarbeitung (1)
- Proliferation (1)
- Propenderivate (1)
- Proteasen (1)
- Protein Expression (1)
- Protein crystal (1)
- Protein-Protein-Wechselwirkung (1)
- Proteinbindung (1)
- Proteine (1)
- Protic Ionic Liquids (1)
- Protonen-NMR-Spektroskopie (1)
- Präamplifizierung (1)
- Pulmonale Applikation (1)
- Pulmonary delivery (1)
- Purity control (1)
- Pyridin (1)
- Pyrimidinone (1)
- Pyroglutaminsäure (1)
- Quality ccontrol (1)
- Quantitative 1H NMR (1)
- Quantitative structure-property relationship modeling (QSPR) (1)
- Quinolone Amides (1)
- Quinolone amides (1)
- RESP model (1)
- Radioindikator (1)
- Radiopharmaka (1)
- Reaktive Zwischenstufe (1)
- Receptor Dynamics (1)
- Red Fruit Oil (1)
- Red Sea (1)
- Release system (1)
- Reproducibility challenges (1)
- Rhizom (1)
- Rifampicin (1)
- Risikobewertung (1)
- Risk Assessment (1)
- Robuvit\(^®\) (1)
- Ruxolitinib (1)
- Röstkaffee (1)
- SPECT (1)
- Salz (1)
- Schafgarbe <Gattung> (1)
- Schistosomiasis (1)
- Schleim (1)
- Schnelltest (1)
- Schwämme (1)
- Seide (1)
- Seiden-Fibroin (1)
- Sekundärmetabolit (1)
- Sensor (1)
- Sensoren (1)
- Sensors (1)
- Sesquiterpene lactones (1)
- Sesquiterpenlactonen (1)
- Shelf-life (1)
- Signaltransduktion (1)
- Silibinin (1)
- Silibinin ester (1)
- Silk Fibroin (1)
- Silk-Fibroin (1)
- Site-specific protein conjugation (1)
- Solubility (1)
- Sorafenib (1)
- Species Differences (1)
- Spectrofluorimetry (1)
- Speziesunterschiede (1)
- Spray drying (1)
- Springs and Parachutes (1)
- Sprühtrocknung (1)
- Stability (1)
- Stabilitätsstudien (1)
- Statine (1)
- Stereoselektive Synthese (1)
- Sternpolymere (1)
- Stoffwechsel (1)
- Streptomyces axinellae (1)
- Streptomycin (1)
- Strychnin (1)
- Strychnosalkaloide (1)
- Synthetische Biologie (1)
- Sythese (1)
- T cell (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TDDFT (1)
- TDM (1)
- TGF-β3 (1)
- Tandem Mass Spectrometry (1)
- Tanzania (1)
- Tetrahydro-15aH-azocino[1 (1)
- Tetrahydro[1 (1)
- Tetrahydrochinazoline (1)
- Therapeutisches Drug Monitoring (1)
- Tierversuche (1)
- Tongue (1)
- Toxicokinetics (1)
- Toxikokinetik (1)
- Transgene Tiere (1)
- Trennung (1)
- Trypanosomen (1)
- Tuberculosis (1)
- Tuberkulose (1)
- Ugi-azide reaction (1)
- Universität Würzburg. Lehrstuhl für Pharmazeutische Technologie und Biopharmazie (1)
- Unterernährung (1)
- V. wallichii (1)
- Validierung (1)
- Vascularisation (1)
- Verderb (1)
- Verkapselung (1)
- Weakly chromophore impurities (1)
- West Africa (1)
- Wissenschaftliches Arbeiten (1)
- Wurmmittel (1)
- Xanomeline (1)
- Zelloberfläche (1)
- Zellwand (1)
- Zunge (1)
- Zytotoxizität (1)
- \(^{1}\)HNMR (1)
- absolute bioavailability (1)
- absorption (1)
- acebutolol (1)
- acetic acid (1)
- acetones (1)
- acetonitrile (1)
- acetylcholinesterase (1)
- acid value (1)
- acids (1)
- activation (1)
- additive manufacturing (1)
- adipose tissue (1)
- adipose tissue engineering (1)
- advanced drug delivery system (1)
- afatinib (1)
- affinity (1)
- agar diffusion test (1)
- albumin (1)
- aldehydes (1)
- alignment (1)
- alkylpyrazines (1)
- allergic rhinitis (1)
- allosteric modulation (1)
- amber codon suppression (1)
- amber light (1)
- amino acid (1)
- amorphous solid dispersion (1)
- ampicillin (1)
- amyloid beta (1)
- amyloid-β (Aβ) (1)
- angiotensin II type 1 receptor (1)
- animal studies (1)
- anisotropy (1)
- anti-infectives (1)
- anti-inflammatory activity (1)
- anti-inflammatory cytokines (1)
- anti-proliferative effects (1)
- anti-protease (1)
- anti-schistosomal activity (1)
- anti-trypanosomal (1)
- antibacterial activity (1)
- antibacterials (1)
- antibiotic (1)
- antibiotic bone concentration (1)
- antifungal drug (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiviral agents (1)
- at-home sampling (1)
- autoinjector (1)
- autophagy (1)
- baclofen homologues (1)
- beta-lactam (1)
- beta-lactam antibiotics (1)
- bile (1)
- bile salt (1)
- binding analysis (1)
- bio-orthogonal chemistry (1)
- bioactivity (1)
- bioavailability (1)
- bioceramics (1)
- biochemical simulations (1)
- biocide polyhexamethylene biguanide (1)
- bioconjugation (1)
- biodegradable polymer (1)
- biodiversity (1)
- bioisosterism (1)
- biologics (1)
- biologische Körperflüssigkeiten (1)
- biomaterials (1)
- biophysics (1)
- bioresponsive (1)
- biosensor (1)
- biosynthesis (1)
- bitopic hybrid ligands (1)
- bitopic ligand (1)
- bitopic ligands (1)
- blood brain barrier (1)
- blood plasma (1)
- boat conformation (1)
- bone marrow (1)
- bone penetration (1)
- bronchial tissue (1)
- brucei (1)
- cAMP (1)
- cGMP (1)
- caffeic acid bornyl ester (1)
- carbamate (1)
- cardiac innervation imaging (1)
- cardiac neurohormonal system (1)
- cartilage (1)
- cartilage tissue engineering (1)
- cecropia telenitida (1)
- cefotiam (1)
- cell metabolism (1)
- cells (1)
- cerebEND cells (1)
- cerulenin (1)
- chemical crosslinking (1)
- chemically programmable (1)
- chemisch programmierbar (1)
- chemotherapy (1)
- chenopodium quinoa (1)
- chiral (1)
- chiral resolution (1)
- chirale Trennung (1)
- cholesterol and oxy-cholesterol (1)
- cholinergic system (1)
- cholinesterase (1)
- cholinesterase inhibitors (1)
- cholinesterases inhibitors (1)
- chronic IBD model (1)
- circular dichroism (1)
- citrus (1)
- clinical pharmacy (1)
- co-delivery (1)
- cocrystal (1)
- cofactors (biochemistry) (1)
- cold stress (1)
- colloid (1)
- commercial preparations (1)
- complementary medicine (1)
- computational chemistry (1)
- contaminants (1)
- coupled (1)
- crithidia fasciulata (1)
- cyclodextrins (1)
- cysteine protease (1)
- cystic fibrosis (1)
- cytokine modulation (1)
- cytokine production (1)
- cytotoxicity (1)
- dabrafenib (1)
- decafluoroazobezene (1)
- dehydration (1)
- derivates (1)
- design of experiments (1)
- detector (1)
- diabetes (1)
- diketopiperazines (1)
- dimeric strychnine ligands (1)
- discovery (1)
- dissolution (1)
- dissolution rates (1)
- dose individualization (1)
- dose linearity (1)
- drug formulation (1)
- drug impurities (1)
- drug metabolism (1)
- drug monitoring (1)
- drug-delivery systems (1)
- dualsteric (1)
- dualsteric ligand (1)
- effector Treg (eTreg) (1)
- efflux pumps (1)
- electroactive (1)
- electrohydrodynamic (1)
- electrophoresis (1)
- electrospun fibers (1)
- emulsions oil-in-water (1)
- enantiomerenrein (1)
- enantiomers (1)
- enantiopure (1)
- enantioselectivity (1)
- enoyl reductase (1)
- enoyl-ACP reductase inhibitors (1)
- enterohepatic recirculation (1)
- enzyme kinetics (1)
- enzymes (1)
- ephedrine (1)
- epitope mapping (1)
- ester value (1)
- ethanol (1)
- ethers (1)
- eugenyl cinnamate (1)
- evaporation based detectors (1)
- evaporationsbasierte Detektoren (1)
- ex vivo Modell (1)
- exchange reaction (1)
- excipient (1)
- experimental visceral leishmaniasis (1)
- extra cellular matrix (1)
- extraction (1)
- fatty acids (1)
- fenoterol (1)
- field testing (1)
- flavonoid (1)
- flavonoids (1)
- fluorescence (1)
- fluorescence polarization (1)
- fluorescence resonance energy transfer (1)
- fluorescent ligands (1)
- fluorescent probes (1)
- fluorine-18 (1)
- fluoroquinolone (1)
- fluticasone propionate (1)
- flux (1)
- food (1)
- forms (1)
- formulation development (1)
- fragment screening (1)
- fragment-based design (1)
- free fatty acids (1)
- funktionale Präpolymere (1)
- gallotannins (1)
- gastrointestinal (1)
- genetic codon expansion (1)
- genetics (1)
- gentamicin sulfate (1)
- glucos metabolism (1)
- glucose (1)
- glutamates (1)
- glutathione (1)
- glycocalyx (1)
- glycolytic flux control (1)
- gprotein (1)
- gradient HPLC–UV (1)
- gut microbiota; bioactivation; polyphenols; complex carbohydrates; tryptophan (1)
- hMSC-TERT (1)
- halo olefines (1)
- head and neck carcinoma (1)
- heart failure (1)
- hepatotoxicity (1)
- high performance liquid chromatography (1)
- high throughput screening (1)
- high-resolution tandem mass spectrometry (1)
- high-throughput screening (1)
- histamine (1)
- history (1)
- homodimerization (1)
- homology modeling (1)
- honeybee (1)
- honeybees (1)
- human African trypanosomiasis (1)
- human nutrition (1)
- human plasma (1)
- human receptor kinetics (1)
- hybrid ligands (1)
- hybrid molecules (1)
- hydnocarpin (1)
- hydrogels (1)
- hydrogen bonding (1)
- hydrogen bonding mycobacterium tuberculosis (1)
- hydrolysis (1)
- hydroperoxides (1)
- hydroxy-dabrafenib (1)
- hypoxia (1)
- hysterectomy (1)
- imaging (1)
- immunomodulatory (1)
- impurities (1)
- in vitro dissolution methods (1)
- in vitro dissolution testing (1)
- in vitro-in vivo correlation (1)
- in vitro/in vivo Korrelation (1)
- in vitro/in vivo correlation (1)
- in vivo dissolution (1)
- information technology (1)
- inhibitors (1)
- injectable protein formulation (1)
- interleukin-4 (1)
- internal transcribed spacer 2 (1)
- intestinal mucus (1)
- intestinal permeability (1)
- intramolecular Michael addition (1)
- intranasal corticosteroids (1)
- intrinsic metabolism (1)
- invasion (1)
- iodine value (1)
- ion-pair chromatography (1)
- ionic liquids (1)
- ipratropium bromide (1)
- isocyanide multicomponent reactions (1)
- isolation (1)
- isomerization (1)
- isosteviol sodium (1)
- isotope ratio mass spectrometry (1)
- isotopically labelled peptides (1)
- jaw bone (1)
- kappa-B activation (1)
- kasA (1)
- ketamine (1)
- kinase inhibitor (1)
- kinase inhibitors (1)
- lactams (1)
- lattice forces (1)
- leaves (1)
- linear discriminant analysis (1)
- lipid deterioration (1)
- lipid deterioration markers (1)
- liposomes (1)
- liquid chromatography electrospray ionization tandem mass spectrometry (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liquid chromatography-mass spectrometry (1)
- liver (1)
- liver impairment (1)
- lowering lattice forces (1)
- lung perfusion model (1)
- mRNA level (1)
- mRNA-Spiegel (1)
- maceration (1)
- macrophages (1)
- magnesium stearate (1)
- mammary gland (1)
- manufacturer (1)
- marine metagenomics (1)
- marine natural products (1)
- marine organisms (1)
- maritime pine bark extract (1)
- matrix metalloproteinase (1)
- matrix metalloproteinases (1)
- mechanistic drug-drug interactions (1)
- mechanistische Arzneistoffinteraktionen (1)
- mechanochemical degradation (1)
- medicine authentication tools (1)
- melanoma (1)
- melatonin (1)
- mercapturic acids (1)
- metabolic glycoengineering (1)
- metabolic network (1)
- metabolic network model (1)
- metabolisches Netzwerk (1)
- metastasis (1)
- micelles (1)
- microscopy (1)
- microspheres (1)
- mixed-mode chromatography (1)
- mobile apps (1)
- modelling (1)
- modified monosaccharides (1)
- molecular biopharmaceutics (1)
- molecular dynamics (1)
- molecular mechanics (1)
- molecular systematics (1)
- molekulares Modellieren (1)
- monoclonal antibodies (1)
- monoklonale Antikörper (1)
- mucin (1)
- multicomponent Ugi-type reaction (1)
- muscarinic (1)
- muscarinic M1 receptor (1)
- muscarinic acetylcholine receptor (1)
- muscarinic acetylcholine receptors (1)
- mycobacterium tuberculosis (1)
- natural product (1)
- natural product hybrids (1)
- nerve agent (1)
- neuroblastoma cell (1)
- neuroprotective (1)
- neuroprotectivity (1)
- nicotinic receptors (1)
- nitric oxide (1)
- non-chromophore analytes (1)
- non-racemic (1)
- nonhuman primates (1)
- novel nepetolactone derivative (1)
- nuclear cardiology (1)
- nuclear magnetic resonance spectroscopy (1)
- oak wood (1)
- oak wood extract (1)
- obtusifolia bertol (1)
- octopamine receptors (1)
- oleanane saponins (1)
- online monitoring system (1)
- opioid ligands (1)
- opioid receptors (1)
- oral anticancer drugs (1)
- oral drug absorption (1)
- oral microbiome (1)
- osimertinib (1)
- osteochondral implant (1)
- oxidative stress (1)
- oxime (1)
- oxygen (1)
- oxytosis/ferroptosis (1)
- paraffins (1)
- parasite (1)
- paromomycin (1)
- patch clamp recording (1)
- pefloxacin (1)
- pentacyclic triterpene (1)
- peptide sensors (1)
- peptide stapling (1)
- perfluoroarylation (1)
- peri-implant disease (1)
- personalized antimicrobial therapy (1)
- pharmacodynamic (1)
- pharmacokinetic (1)
- pharmacological evaluation (1)
- pharmacology (1)
- pharmacometrics (1)
- phosphoglycolate phosphatase (1)
- photocontrol (1)
- photopharmacology (1)
- phylogenetic analysis (1)
- phylogenetic tree (1)
- phylogeny (1)
- phytochemicals (1)
- phytochemistry (1)
- phytomedicine (1)
- phytoneering (1)
- pig (1)
- pine bark extract (1)
- piperacillin/tazobactam (1)
- plant extract (1)
- plants (1)
- plasma proteins (1)
- podophyllotoxin (1)
- poly(2-ethyl-2-oxazoline) (1)
- polyethylenglykole (1)
- polylactid (1)
- polymer drug interaction (1)
- polymer processing (1)
- polymers (1)
- polysorbate 80 (1)
- poor water-soluble drugs (1)
- poorly water soluble drugs (1)
- posaconazole (1)
- post-operative recovery (1)
- post-surgery recovery (1)
- postsurgical adhesion (1)
- pressurized microwave‐assisted extraction (1)
- principal component analysis (1)
- pro-inflammatory cytokines (1)
- profiles (1)
- proliferation (1)
- propionate (1)
- protease inhibition (1)
- protease inhibitors (1)
- protease-sensitive release (1)
- proteasome system (1)
- protein engineering (1)
- protein modification (1)
- protein nebulization (1)
- protein therapeutics (1)
- psidium guajava; (1)
- pulmonary absorption (1)
- purification (1)
- pyridine (1)
- pyridobenzodiazepine (1)
- pyroglutamic acid (1)
- qNMR (1)
- qPCR (1)
- quality evaluation (1)
- quantitative 1H NMR (1)
- quantum mechanics (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- randomized controlled study (1)
- rat study (1)
- reactive metabolites (1)
- reaktive Metabolite (1)
- receptors (1)
- red blood cells (1)
- red fruit oil (1)
- renal cell carcinoma (1)
- renin-angiotensin system (1)
- replica-exchange molecular dynamics (1)
- required hydrophilic–lipophilic balance (1)
- residence time (1)
- resistance (1)
- response surface (1)
- ribosomal RNA (1)
- roast coffee (1)
- ruxolitinib (1)
- sacha inchi oil (1)
- saponification Value (1)
- saturation transfer difference NMR (1)
- scar revision surgery (1)
- schistosmiasis (1)
- schistosoma (1)
- schistosomula (1)
- secondary structure (1)
- secretion (1)
- sensor (1)
- sensory chewing gums (1)
- serjanic acid (1)
- serum (1)
- short-range order (1)
- silk fibroin (1)
- silybin (1)
- simple (1)
- simulated intestinal fluid (1)
- single-molecule microscopy (1)
- sisomicin (1)
- site-specific protein modification (1)
- soil-transmitted helminthiases (1)
- solid dispersion (1)
- solid-state NMR spectroscopy (1)
- spectrofluorimetry (1)
- sphingomonads (1)
- spray (1)
- steered molecular dynamics (1)
- sterubin (1)
- streptomyces (1)
- structural elucidation (1)
- structure–activity relationships (1)
- strychnine (1)
- subcutaneous fat layer (1)
- substandard and falsified medicines (1)
- surface functionalization (1)
- synovial fluid (1)
- system (1)
- tacrine (1)
- tandem mass spectrometry (1)
- tetromycin (1)
- therapeutic gases (1)
- thermodynamics (1)
- thin-layer chromatography (1)
- thymyl cinnamate (1)
- tofacitinib (1)
- tongue (1)
- topical treatment (1)
- toxicity (1)
- track and trace (1)
- trametinib (1)
- transglutaminase (1)
- transport (1)
- treatment regimens (1)
- triacylglycerides (1)
- trypanosoma cruzi (1)
- tuberculosis (1)
- type 2 diabetes (1)
- underutilized legumes (1)
- unnatural amino acid (1)
- unsaturated fatty acids (1)
- urolithins (1)
- ursolic acid (1)
- vacuoles (1)
- validation (1)
- valsartan (1)
- valtrates (1)
- vascularized fat construct (1)
- veterinarians (1)
- veterinary medicine (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- volumetric absorptive microsampling (1)
- Öl (1)
- β2 - Agonisten (1)
- β2 - agonist (1)
Institute
- Institut für Pharmazie und Lebensmittelchemie (208) (remove)
Sonstige beteiligte Institutionen
- Universität Belgrad, Serbien (2)
- ACC GmbH Analytical Clinical Concepts (1)
- Apotheke, Universitätsklinikum Würzburg (1)
- Bundesinstitut für Arzneimittel und Medizinprodukte (1)
- Friedrich-Schiller-Universität Jena (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-9708 Wuerzburg, Germany (1)
- Helmholtz Institute for RNA-based Infection Biology (HIRI), Josef-Schneider-Straße 2/D15, DE-97080 Wuerzburg, Germany (1)
- IBMP - Institut für Biomedizinische und Pharmazeutische Forschung in Nürnberg-Heroldsberg (1)
- Johns Hopkins School of Medicine (1)
- Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg (1)
- Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, DE-37077 Goetingen, Germany (1)
- Novartis AG (1)
- Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland (1)
- Novartis Pharma AG, Switzerland (1)
- Pharmakologie, Universität Bonn (1)
- Pharmazie, Universität Mailand (1)
- Spectral Service AG (1)
- Tanzania Food and Drugs Authority (1)
- Universitätsklinikum Würzburg (1)
- Zentraleinheit Klinische Massenspektrometrie (1)
- Zentrallabor, Universitätsklinikum Würzburg (1)
EU-Project number / Contract (GA) number
- 26230120009 (1)
- 296679 (1)
- 314911 (1)
- 701983 (1)
Conjugation of reactive intermediates of drugs with proteins or DNA may result in toxic effects such as hepatotoxicity, agranulocytosis, allergies, tumors, etc. From 1975 to 1999, 2.9% of drugs were withdrawn from the market due to such severe adverse drug reactions. Thus, formation of chemically reactive intermediates is a widely discussed problem in drug development processes. Early detection of potentially toxic compounds is required for drug discovery and drug development. Conjugation of such electrophilic compounds with glutathione (GSH) is one of the most important detoxifying reactions in vivo. Processing of these GSH-conjugates ultimately leads to the formation of renally cleared mercapturic acids, which may also be oxidized to sulfoxides. Thus, mercapturic acids may be generated and detected in vitro and non-invasively in vivo in urine to assess the reactivity of a compound in early stages of drug development processes. Therefore, the aim of this work was to develop and evaluate a HPLC-MS/MS screening method for simple and rapid detection and characterization of known and unknown mercapturic acids and application of the method to several different matrices. Based on the common constant neutral loss (CNL) of 129 Da of all mercapturic acids tested (in negative ion mode), a CNL survey scan was performed using a linear ion trap instrument and was combined with two enhanced product ion (EPI) scans with different collision energies to characterize the detected signals. The CNL resulted from the cleavage between the sulfur and the carbon atom in the N-acetyl-L-cysteine moiety. After optimization of the experimental parameters, the detection limits of the reference substances in rat urine ranged from 0.3 to 15.5 pmol on column (i.e. 20 ng/ml to 800 ng/ml). For in vitro evaluation of the method, the model compounds acetaminophen, diclofenac, bifonazole, clozapine, troglitazone, carbamazepine, and bisphenol A were screened for formation of reactive intermediates and, hence, detection of the corresponding mercapturic acids. To determine possible species- and tissue-specific toxicities, the model compounds were incubated with stimulated neutrophils and with liver microsomes from rats and humans. Species-specific differences were observed in incubations of acetaminophen and diclofenac with rat and human hepatic microsomes. Tissue-specific differences in biotransformation of the model compounds in incubations with human neutrophils and human liver microsomes were observed for diclofenac, carbamazepine, clozapine, and bifonazole. The developed HPLC-MS/MS method was also evaluated in vivo by analysis of rat and human urine. Drug-related mercapturic acids were detected in urine of rats orally treated with acetaminophen (20 mg/kg and 640 mg/kg b.w.) or diclofenac (10 mg/kg and 20 mg/kg b.w.). Human urine samples were analyzed before and after oral administration of a clinically used dose of 500 mg and 50 mg of acetaminophen. Besides detection of the mercapturic acid of N-acetylbenzoquinoneimine (AAP-MA), a second mercapturic acid with m/z 327 occurred dose-dependently in rat and human urine samples after administration of acetaminophen. Further investigations on identification of this metabolite using authentic compounds and comparing their MS/MS mass spectra demonstrated oxidation of AAP-MA to stereoisomeric sulfoxides in vivo. For diclofenac, a novel mercapturic acid with m/z 441 was detected in rat urine samples that was identical to a metabolite obtained in incubations with human neutrophils before. The in vivo formation of this diclofenac metabolite is described here for the first time. In addition, three endogenously formed mercapturic acids were detected and identified. In conclusion, the results of the in vitro and in vivo evaluation demonstrate the advantages of the rapid and generic HPLC-MS/MS screening method for the detection of mercapturic acids, that can be obtained with a minimum of sample preparation and a high throughput in diverse matrices.
The cyclic nucleotides cAMP and cGMP are two ubiquitous important second messengers, which regulate diverse physiological responses from vision and memory to blood pressure and thrombus formation. They act in cells via cAMP- and cGMP-dependent protein kinases (PKA and GK), cyclic nucleotide-gated channels and Epac. Although the concept of cyclic nucleotide signalling is well developed based on classical biochemical studies, these techniques have not allowed to analyze cAMP and cGMP in live cells with high temporal and spatial resolution. In the present study fluorescence resonance energy transfer was used to develop a technique for visualization of cAMP and cGMP in live cells and in vitro by means of fluorescent biosensors. Ligand-induced conformational change in a single nucleotide-binding domain flanked with green fluorescent protein mutants was used for dynamic, highly sensitive measurements of cAMP and cGMP. Such biosensors retained binding properties and chemical specificity of unmodified domains, allowing to image cyclic nucleotides in a physiologically relevant range of concentrations. To develop cAMP-sensors, binding domains of PKA, Epac and cAMP-gated HCN-channel were used. cGMP-sensors were based on single domains of GK and phosphodiesterases (PDEs). Sensors based on Epac were used to analyze spatio-temporal dynamics of cAMP in neurons and macrophages, demonstrating that cAMP-gradients travel with a high speed (~ 40 μm/s) throughout the entire cytosol. To understand the mechanisms of cAMP-compartmentation, kinetics properties of phosphodi-esterase (PDE2) were, next, analyzed in aldosterone producing cells. PDE2 is able to rapidly hydrolyze extensive amounts of cAMP, so that the speed of cAMP-hydrolysis is much faster than that of its synthesis, which might serve as a basis of compartmentation. cAMP-sensors were also used to develop a clinically relevant diagnostic method for reliable detection of β1-adrenergic receptor autoantibodies in cardiac myopathy patients, which has allowed to significantly increase the sensitivity of previously developed diagnostic approaches. Conformational change in a single binding domain of GK and PDE was, next, used to create novel fluorescent biosensors for cGMP. These sensors demonstrated high spatio-temporal resolution and were applied to analyze rapid dynamics of cGMP production by soluble and particulate guanylyl cyclases as well as to image cGMP in mesangial cells. In summary, highly sensitive biosensors for cAMP and cGMP based on single cyclic nucleotide-binding domains have been developed and used in various biological and clinically relevant applications.
Synthesis of (RS)-5-amino-3-aryl (methyl)-pentanoic acid hydrochlorides, 3 aminomethyl-5-chloro-benzoic acid hydrochloride and (RS)-4-amino-3-(4`-ethynyl(iodo)-phenyl)-butanoic acid hydrochlorides have been accomplished. The aim of their synthesis was to evaluate their GABABR agonist activity and to derive a model which will correlate their structure with the observed pEC50. The GABABR agonist activity of the prepared compounds has been determined in functional assay based on calcium measurement in vitro using tsA cells transfected with GABAB1b/GABAB2/Gαq-z5. Reviews on the neurotransmitter receptors (ligand-gated ion channel receptors and G protein-coupled receptors), their agonists and antagonists have been given in the general part of this work. A detailed discussion on the strategy followed for the synthesis of the designed compounds as well as the starting materials and intermediates has been described and illustrated in Schemes 2-6. The synthesized compounds were evaluated for their GABABR agonist activity. Furthermore, these compounds were docked in the available 3D homology model of GABABR using the program FlexiDock implemented in SYBYL software. Subsequently, we derived a predictive model which correlates the experimentally determined pEC50 with the calculated binding energy of certain baclofen analogues and homologues. In addition, we used the program DISCO (DIStance COmparisons) implemented in SYBYL software to find the pharmacophore features of GABAB agonists.
The study deals with the area of the allosteric modulation of the muscarinic M2 receptors. The allosteric modulators have an influence on binding of orthosteric ligands (agonists and antagonists) to the classical orthosteric binding site of the muscarinic M2-receptors. The modulators are able to enhance (positive cooperativity) or decrease (negative cooperativity)the affinity of ligands to the orthosteric binding site. The allosteric binding site is located at the entrance of the receptor binding pocket. It is less conserved than the orthosteric binding site which is located in a narrow cavity created by the seven transmembrane domains. Consequently, development of subtype selective allosteric ligands is easier than subtypeselective muscarinic agonists or antagonists. Furthermore, subtype selectivity can be achieved by differently cooperative interactions between the allosteric and orthosteric ligand at different receptor subtypes. For example, the allosteric modulators that are positively cooperative with ACh at M1 receptors and neutrally cooperative at the other receptor subtypes could be beneficial for treatment of the Alzheimer’s disease. Bisquaternary analogues of the Strychnos alkaloid caracurine V are among the most potent allosteric modulators of muscarinic M2-receptors. The very rigid ring skeleton comprises the pharmacophoric elements of two positively charged nitrogens at an approximate distance of 10 surrounded by two aromatic ring systems in a distinct spatial arrangement. Owing to the close structural relationship of caracurine V salts to the strong muscle relaxants toxiferine and alcuronium, they are likely to exhibit neuromuscular blocking activity, which would limit their usefulness as research tools and make the therapeutical use impossible. Reduction of the caracurine V ring skeletons to structural features responsible for good allosteric potency could possibly lead to compounds with negligible neuromuscular blocking activity and very high affinity to the allosteric binding site at M2 receptor. Thus, the aim of this study was to synthesize and pharmacologically evaluate analogues of a novel heterocyclic ring system, which comprises the pharmacophoric elements mentioned previously. The key step of the synthesis of the desired 6,7,14,15-tetrahydro[1,5]diazocino[1,2-a:6,5-a]-diindole ring system (6) involved the intermolecular double N-alkylation of the bromoethylindole (5), which was prepared from the known indolyl methylacetate (3) by reduction of the ester group to alcohol and subsequent substitution by bromine. 3 could be prepared in three steps involving N,N-dibenzylation of tryptamine followed by introduction of the dimethyl malonate moiety at C-2 of indole ring and a subsequent demethoxycarbonylation. The total synthesis of 6,7,14,15-tetrahydro[1,5]diazocino[1,2-a:6,5-a]diindole ring system (6) is shown in Scheme 24. In order to examine the influence of the length of the side-chain on muscarinic activity,exchange of the ethylamine moieties of 14 by the methylamino groups was planned. This should be accomplished by dimerization of the unsubstituted 2-bromoethylindole (32), and subsequent Mannich aminomethylation of the resulting unsubstituted pentacyclic ring. The total synthesis of the 6,7,14,15-tetrahydro-15aH-azocino[1,2-a:6,5-b]diindole ring system(35) is shown in Scheme 25. 32 was prepared from indole-2-carboxylic acid in six steps involving reduction of the acid to the corresponding alcohol 26, benzoylation of 26 followed by nucleophilic substitution with KCN, hydrolysis of the cyanide 28 to indolyl acetic acid 29,reduction of 29 to the corresponding alcohol 30, and finally bromination of 30 to give the bromide 32. Since dimerization attempts of 32 provided only 2-vinylindole (33), the tosylate 34 was used as starting material for the intermolecular alkylation to give exclusively an isomeric pentacyclic ring system, 7,14,15-tetrahydro-15aH-azocino[1,2-a:6,5-b]diindole (35). The formation of the novel, asymmetric ring skeleton can be explained by the ambident nucleophilic character of the indolyl anion that can be alkylated either at nitrogen or at C-3 of indole ring. 35 was subjected to a Mannich reaction to give 2,13-dimethylaminoalkylated product 37 as well as small amounts of the 13-monosubstituted compound (36). The geometry of novel ring systems 6 was elucidated by means of NMR spectroscopy and semiempirical calculations. The diazocinodiindole ring skeleton of 6 exists in chloroform solution at room temperature in a twisted-boat conformation, as indicated by 600 MHz ROESY experiment, vicinal coupling constants within the eight-membered ring, and AM1 calculations. In order to obtain potent allosteric ligands, the new heterocycles 6 and 37 were quarternized with methyliodide to the corresponding ammonium salts 14 and 38, respectively. Additionally, the N,N -diallylsalts of 37 (compound 39) was prepared. The allosteric effect of 14, 38, and 39 on the dissociation of the orthosteric radioligand [3H]Nmethylscopolamine([3H]NMS) and their effects on [3H]NMS equilibrium binding were studied in homogenates of porcine heart ventricles. The concentration of an allosteric agent for a half-maximum effect on orthosteric ligand dissociation (EC50,diss) corresponds to a 50 % occupancy of the liganded receptors by the respective allosteric test compounds. Due to the presence of two benzyl groups on each nitrogen in the side chains of 14, its binding affinity can be best compared with that of N,N -dibenzylcaracurinium V dibromide (EC50,diss = 69 nM). Compound 14 exhibited the comparable affinity to N,N -dibenzylcaracurinium V dibromide with EC50,diss = 54 nM. This result suggested that replacement of the bulky benzyl groups of 14 by smaller substitutents will probably increase the allosteric potency, since dimethyl- and diallylcaracurinium salts showed a 5-fold increase of binding affinity relative to the dibenzyl analogue. Even though the new azocinodiindole ring system of 38 and 39, is not included in the caracurine V ring skeleton, it comprises the essentially pharmacophoric elements of allosteric potency. Due to the different spatial arrangements of the aromatic rings, as well as to different internitrogen distances in both ring systems, compound 38 and 39 exhibited 4-fold lower M2 binding affinity (EC50,diss = 35 and 48 nM, respectively) than the corresponding caracurine V analogues. This study deals with the synthesis of the first representative (Compound 6) of a novel pentacyclic ring system derived from caracurine V. The high allosteric potency of its dimethyl analogue reveals the [1,5]diazocino[1,2-a:6,5-a]-diindole ring system as a new promising lead structure for allosteric modulators of muscarinic M2 receptors. Future research will be focused on structural modifications of the new ring system in order to increase the affinity to the muscarinic receptors. Furthermore, the binding affinities of the new synthesized compounds to the muscle type of nicotinic ACh-receptor should reveal structural features responsible for the muscarinic/nicotinic selectivity.
Priority tasks of the present thesis were to generate various enantiopure C-3-substituted pyroglutamates as well as C-3-substituted glutamates, and furthermore to ameliorate the serious drawback of the bad atom-economy in the reaction sequence of previously published silylether-mediated procedures. To meet these requirements, the ortho ester functionality (OBO ester) developed by Corey was introduced. According to the plan of synthesis, the starting material, non-racemic (S)-pyroglutamic acid, was converted to the corresponding oxetane ester via a DCC-mediated esterification. The latter was N-protected to provide N-acceptor substituted pyroglutamic acid oxetane esters (Acceptor=Boc,Cbz,CO2Me). After rearrangement with boron trifluoride, the ortho ester derivatives (Acceptor=Cbz,CO2Me) were at hand and exclusively the N-Cbz derivative was converted to the corresponding alpha,beta-unsaturated lactam via a syn-elimination reaction. The formation of the C-3-substituted ortho ester compounds (R=methyl,ethyl,butyl,allyl,phenyl,4-chlorophenyl,biphenyl,naphthyl) was performed via a copper-mediated conjugate addition to the alpha,beta-enone system of the N-Cbz-alpha,beta-unsaturated lactam. The OBO functionality hence was envisaged to support perfect trans selectivity in this cuprate addition to the Michael system of the N-Cbz-alpha,beta-unsaturated lactam. Spectroscopic NMR-data, on the basis of 1H-, 13C- and DEPT spectra, proved the assumption that the C-3-substituted ortho ester derivatives exclusively are trans-configurated, i.e. the alkyl derivatives (R=methyl,ethyl,butyl,allyl) are (2S,3S)-configurated and the aryl derivatives (R=phenyl,4-chlorophenyl,biphenyl,naphthyl) are (2S,3R)-configurated). The C-3-substituted ortho ester derivatives were completely deprotected to yield the C-3-substituted pyroglutamates (R=ethyl,phenyl,4-chlorophenyl,naphthyl). Finally, ring opening reaction via route A-2 lead to the desired enantiopure C-3-substituted glutamates. Alternatively, latter preferably were reacted via route A-1 to yield the C-3-substituted glutamates (R=methyl,ethyl,butyl,phenyl,4-chlorophenyl,naphthyl). Their (2S,3R)-configuration (R=aryl) and (2S,3S)-configuration (R=alky), respectively, unambiguously was proved on the basis of available spectroscopic NMR-data. To ensure this assumption, diastereomeric (2S,3R)-3-methyl glutamic acid (i.e. cis-configurated) examplarily was synthesized via route A-3 and spectroscopic NMR-data was compared to that of (2S,3S)-3-methyl glutamic acid (i.e. trans-configurated). Conclusively, there can be recorded the fact that the serious drawback of the bad atom-economy in the reaction sequence previously used can be circumvented by the introduction of the OBO functionality, so the concept of an improved atom-economy is achieved. Additionally, in comparison to the silyl-ether-mediated synthesis, the OBO functionality provided crystalline ortho ester derivatives, which facilitated their purification as well as characterization.
The 2-halo imidoyl chlorides 7 are obtained from the amide 5 and the 2-halo amides 6 by the action of phosphorus pentachloride and thionyl chloride, respectively. Non-racemic (S)-6a is converted into 7a which is racemic, however. The reaction of Lawesson's reagent with 6a furnishes the diastereomeric 1,3.2-thiazaphospholidine derivatives 15. Treatment of (S)-6a (98% eel with methyl triflate affords 2-chloro imidate 8 (95% eel which reacts with methanamine in the presence of methanammonium chloride to yield the 2-chloro amidine (S)-9a (90% eel. The 2-halo imidoyl halides 7a and b react with methanamine to produce the 2-halo amidines 9a and b. - Strong bases, e.g. potassium tert-butoxide or sodium hydride in the presence of catalytic amounts of tertbutyl alcohol, eliminate hydrogen chloride or bromide from the 2-halo amidines 9a and band (S)-9a to yield mixtures of Recently, we demonstrated that the formation of the chiral non-racemic aziridinone (R)-2 from the a-chloro amide (5)-1 by base-promoted dehydrochlorination[2) as well as the nucleophilic cleavage of the N-C(3) bond of (R)_2[3,4) occur with inversion of configuration, thus excluding the intervention of achiral (acyclic) intermediates. In the temperature range of lOO-170°C, however, slow racemization accompanies the thermolysis of (R)-2 and indicates the existence of an achiral or a racemic transient, e. g. (M)-3 + (P)-3. Indeed, high-level quantum-chemical calculations reveal that an activation energy of (170 ± 25) kJmol- 1 is required for the unimolecular ring opening of the parent aziridinone which affords a species of high diradical character[41. Subsequently, the unstable N-phenylaziridinone invoked in the decomposition of the (5)-2-bromopropananilide anion was shown to react with tert-butylamine or dimethylformamide with inversion of configuration at C(3)[51. Thus, the stereochemical evidence in the series of 3-alkylaziridinones excludes achiral (acyclic) aziridinone isomers as intermediates at low tempera tures [6J. Similar stereochemical studies are still missing in the related series of iminoaziridines. Therefore, we report on the synthesis and thermolysis of the diastereomeric chiral racemic (E)- and (Z)-(4)[71 and non-racemic iminoaziridines (E,R)- and (Z,R)-4. Racemic Iminoaziridines (E)- and (Z)-4 Though a photochemical route to the iminoaziridines (E)- and (Z)-4 has been devised more recently, i. e. the phothe 2-iminoaziridines (E)- and (Z)-4, and (E,R)- and (Z.R)-4 (83% eel, respectively. The 1.3-elimination of hydrogen bromide from 9b is diastereoselective at -30 to -40°C [(E)-4:(Z)-4 = <10:>90). The diastereomers equilibrate at 36°C with (kEZ + k ZE) = (5.92 ± 0.08) . 10-5 S-I (K = kEZlkzE = 0.428 ± 0.013). - The thermolysis of (E)- and (Z)-4 in [D61benzene solution yields the imine 16 and methyl isocyanide (17). The decomposition follows the first-order rate law. The following Arrhenius and Eyring parameters are calculated from five rate constants obtained in the temperature range of 70-110°C: Ea = (115.2 ± 0.4) kJmol-t, IgA = (12.06 ± 0.28), AH* = (112.1 ± 0.4) kJmol- l , AS'" = (-23.9 ± 0.7) JK-I mol-I, AGj73K = 121 kJmol-1 . The enantiomeric excess of the surviving fraction of (E,R)- and (Z.R)-4 is unchanged after two half-lives at 80°C.
A route to 2S,5S-and 2R,5S-hydroxypipecolic acid is presented, starting with the enantiopure 5S-5-hydroxy-piperidone 7. The key step of this reaction sequence is the chemoselsctive methylenation of the amide carbonyl group of 8 with dimethyltitanocene 9 to 10. The transformation of the exocyclic enecarbamate double bond to the carboxylic acid group is best accomplished via hydroboration/oxidation to the alcohol 11a,b. Separation and oxidation of the dlastereomers 11a,b, to 148. and 14b, and hydrolysis furnishes the diastereomeric pipecolic acids 15a and 15b in enantiopure form.